Novogen Limited
(Public, ASX:NRT) Watch this stockFind more results for
NRT
Advertisement
Key stats and ratios
| Q2 (Jun '09) | 2009 | |
| Net profit margin | -275.40% | -213.39% |
| Operating margin | -275.40% | -213.38% |
| EBITD margin | - | -210.76% |
| Return on average assets | -57.80% | -58.56% |
| Return on average equity | -67.44% | -69.63% |
| Employees | 48 | - |
Address
140 Wicks Road North Ryde
North Ryde, NSW 2113
Australia
+61-2-98780088 (Phone)
+61-2-98780055 (Fax)
North Ryde, NSW 2113
Australia
+61-2-98780088 (Phone)
+61-2-98780055 (Fax)
Website links
Novogen Limited discussions
View all discussions »Description
Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. In February, 2009, the Company announced that it focuses its activities on its oncology program. The Company operates subsidiary companies in 3 geographical areas: Australia, North America and Europe. The subsidiaries are involved in the selling and marketing of Novogen's consumer healthcare products. The Company’s product range includes Phenoxodiol, Triphendiol, NV-128, and GLYC-101. The Company’s subsidiaries include Novogen Laboratories Pty Ltd, Norvogen Pty Ltd, Glycotex, Inc. and Novogen BV.
Officers and directors
| Christopher Naughton | Chief Executive Officer, Managing Director, Executive Director | |
| David R. Seaton CPA | Chief Financial Officer | |
| Warren J. Lancaster | Vice President - Commercial and Corporate Development, US | |
| Ronald Lea Erratt | Company Secretary | |
| Alan J. Husband Ph.D. | Executive Director | |
| Bryan M. Palmer | General Manager - Operations | |
| Craig D. Kearney | General Manager - Consumer Business | |
| Philip A. Johnston | Non-Executive Chairman of the Board | |
| Paul John Nestel M.D. | Non-Executive Director | |
| Geoffrey M. Leppinus | Non-Executive Director |